Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study

[1]  Kazuhiko Yoshida,et al.  Comparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional Study , 2023, Targeted Oncology.

[2]  C. Porta,et al.  Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1). , 2023, Clinical genitourinary cancer.

[3]  David D. Yang,et al.  The Increasing Importance of Rigorous Real-World Evidence , 2022, JNCI cancer spectrum.

[4]  Kazuhiko Yoshida,et al.  Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy for Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria , 2022, Targeted Oncology.

[5]  F. Massari,et al.  Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors. , 2022, European urology focus.

[6]  Tetsutaro Hayashi,et al.  Prediction of early progression of metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitor , 2021, Current urology.

[7]  A. Ardizzoni,et al.  Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials. , 2021, European journal of cancer.

[8]  A. Ardizzoni,et al.  Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: a systematic review. , 2021, Future oncology.

[9]  C. Porta,et al.  Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. , 2021, The New England journal of medicine.

[10]  C. Porta,et al.  Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. , 2021, The New England journal of medicine.

[11]  T. Choueiri,et al.  Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium , 2021, Cancer medicine.

[12]  R. Hinojar,et al.  Hospital Ramón y Cajal, Madrid, Spain. , 2020, European heart journal.

[13]  C. Porta,et al.  Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States. , 2020, Clinical genitourinary cancer.

[14]  T. Choueiri,et al.  Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma. , 2020, JAMA oncology.

[15]  Hematology/Oncology , 2020, Questions from NeoReviews.

[16]  C. Porta,et al.  First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. , 2019, European urology.

[17]  N. Agarwal,et al.  The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma , 2019, Translational cancer research.

[18]  C. Porta,et al.  Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial , 2019, The Lancet.

[19]  T. Powles,et al.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[20]  R. Motzer,et al.  Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[21]  C. Porta,et al.  Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy , 2018, Targeted Oncology.

[22]  P. Russo,et al.  Cytoreductive Nephrectomy - Patient Selection Is Key. , 2018, The New England journal of medicine.

[23]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[24]  Melissa Matz,et al.  Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries , 2018, The Lancet.

[25]  Charles Swanton,et al.  Renal cell carcinoma , 2017, Nature Reviews Disease Primers.

[26]  Erich P Huang,et al.  RECIST 1.1-Update and clarification: From the RECIST committee. , 2016, European journal of cancer.

[27]  T. Choueiri,et al.  Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. , 2014, European urology.

[28]  P. Borgia,et al.  Deliveries and induced abortions at the San Camillo-Forlanini Hospital, Rome, Italy , 2014 .

[29]  T. Choueiri,et al.  Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  C. Sternberg,et al.  Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[32]  A. Wernick.  University , 2006, The Genealogical Imagination.

[33]  C. Tangen,et al.  Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. , 2005, The Journal of urology.

[34]  S. Schmidt,et al.  Bonn, Germany , 2019, The Statesman’s Yearbook Companion.